Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Eldad J Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Elinor Sabbag, BSc., Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Rosa Ruchlemer, MD, Roxolyana Abdah-Bortnyak, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Netanel Horowitz, David Lavie, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2014) 124 (21): 4409.

https://doi.org/10.1182/blood.V124.21.4409.4409

Published: 2014

Journal Articles

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Eldad J Dann, MD, Zeev Blumenfeld, MD, Rachel Bar-Shalom, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Odelia Goor, MD, Diana Libster, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2011) 118 (21): 1564.

https://doi.org/10.1182/blood.V118.21.1564.1564

Published: 2011

Journal Articles

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Liana Abdach, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Jacob M. Rowe, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MSc, FRCPC

Blood (2010) 116 (21): 2809.

https://doi.org/10.1182/blood.V116.21.2809.2809

Published: 2010

Journal Articles

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Menachem Ben-Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Hanna Rosenbaum, MD, Riva Fineman, MD, Odelia Goor, MD, Diana Libster, MD, Zeev Blumenfeld, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2009) 114 (22): 1552.

https://doi.org/10.1182/blood.V114.22.1552.1552

Published: 2009

Journal Articles

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Eldad J. Dann, MD, Ada Tamir, PhD, Ron Epelbaum, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Rachel Bar-Shalom, MD

Blood (2008) 112 (11): 1452.

https://doi.org/10.1182/blood.V112.11.1452.1452

Published: 2008

Journal Articles

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Eldad J. Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Nissim Haim, MD, Irit Avivi, MD, Diana Gaitini, MD, Menachem Ben-Shachar, MD, Ora Israel, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2006) 108 (11): 4589.

https://doi.org/10.1182/blood.V108.11.4589.4589

Published: 2006

Journal Articles

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Eldad J. Dann, Rachel Bar-Shalom, Ada Tamir, Nissim Haim, Menachem Ben-Shachar, Irit Avivi, Tzila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, Ron Epelbaum

Blood (2006) 109 (3): 905–909.

https://doi.org/10.1182/blood-2006-04-019901

Published: 2006

NARROW

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Email alerts

ASH Publications

American Society of Hematology

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only